



TOOLKIT GUIDE OVERVIEW & INSTRUCTIONS FOR USE

We hope you are as excited as we are to spread the word about **YUVEZZI™** (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%!

This document provides instructions on how to use the communications materials within the provider toolkit to help you share this news with your patients. **The materials included in the YUVEZZI ECP Toolkit are:**

- > Press release template
- > e-Blast
- > Sample website language and visual assets
- > Social media posts
- > Ready for YUVEZZI Animated Video
- > FAQ
- > Fact Sheet

These materials are intended for use by eye care professionals and office staff only as instructed, and for communication about YUVEZZI consistent with the toolkit instructions. Eye care professionals and office staff who receive these materials can utilize the materials for as long as they are approved and accurate. The materials are not for use outside of the U.S., and not for audiences or channels not specifically contemplated by the toolkit.

If you have any questions about toolkit components or how to use them, please contact your local YUVEZZI sales representative or call **1-866-2-YUVEZZI** to be connected with a representative.

GENERAL INSTRUCTIONS & GUARDRAILS

Download the YUVEZZI ECP Toolkit file or individual material to your computer. From there, open the desired material to print or share digitally, in its entirety, with your network. Instructions and guardrails for each material are detailed in the following pages.

PLEASE NOTE: All materials must be used exactly as written in their entirety, with no alterations to the text, except where explicitly noted (e.g., to insert your name or practice information). Use/distribute the materials only as intended and described within this toolkit.

Do not:

- > **Revise, abbreviate or reformat the materials in any way**
- > **Remove or obscure branding, logos, references, safety language, fair balance, or copyright notices**
- > **Combine toolkit content with other promotional or educational materials unless expressly permitted**
- > **Use individual claims, images, or statements from the toolkit separately to create new content**

As a reminder, Tenpoint Therapeutics, Ltd., is not responsible for your social media materials or activities. Eye care professionals are responsible for the content of their posts, including, without limitation, adding any additional disclaimers that may be required by applicable laws or regulations.

If you become aware of an adverse event, side effect, or product complaint in connection with use of these materials or social media engagement, you are encouraged to report it to the FDA. Visit www.fda.gov/medwatch, or call **1-800-FDA-1088**.

After you have let your social media followers know about YUVEZZI, remember to check out the YUVEZZI Facebook page at www.facebook.com/YUVEZZIecp and on Instagram at www.instagram.com/yuvezzi_ecp/. You can like, follow and share our posts with your own social networks!

PRESS RELEASE TEMPLATE

Used to share the news of YUVEZZI™ availability at your practice via your website or other press release distribution channels, as well as local media outlets.

There is an opportunity to insert your name, practice details and logo in the fields noted in pink. You may also select a preferred quote to use in the press release of three available options. Once you select the quote that you prefer, the other options should be deleted. Please do not alter the quote copy in any way.



E-BLAST

Used to share in the body of an email the news of YUVEZZI™ availability at your practice with patients. There is an opportunity to insert your practice name and phone number in the fields highlighted in pink.

New message

Subject: Struggling to Read Close Up? YUVEZZI™ Eye Drops May Help

Dear patients,

Have you noticed simple things like reading, texting or checking a label have become harder without holding objects farther away? *It's not just you.*

I am excited to announce that YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% eye drops are available by prescription in our practice as an innovative option for patients facing blurry close-up vision due to age, a condition called presbyopia.¹

Presbyopia, the gradual loss of close-up vision that typically begins around age 45,² is a natural, inevitable part of aging. The lens in your eye stiffens slowly over time, making it harder to focus on close-up objects like text messages, menus, or small print.³

We know many patients are looking for ways to manage presbyopia, and the best option is often unique to their lifestyle. YUVEZZI is the first and only eye drop that combines two active ingredients that work together to treat age-related blurry close-up vision (presbyopia).

What you can expect with YUVEZZI

YUVEZZI is a once daily, fuss-less eye drop for presbyopia that can be used your way:

- On its own instead of reading glasses; **OR**
- With contacts or glasses you use to see far away.*

In medical studies, YUVEZZI provided up to 8 continuous hours of improved close-up vision.⁴ As soon as 30 minutes after taking YUVEZZI, some people could clearly read at least 3 more lines on an eye chart in low light without losing distance vision.⁴

Please see full Important Safety Information below and [Brief Summary](#) for more information.

We are excited to provide this new option in our practice. To learn more, contact [\[insert practice name\]](#) at [\[insert practice phone number\]](#) or visit [www.YUVEZZI.com](#).

NOW AVAILABLE



*If you wear contact lenses, remove them before using YUVEZZI. Wait at least 10 minutes after using YUVEZZI before you put them back in your eyes.

**About half of people in medical studies could read close up at hour 8.

YUVEZZI Indication and Important Safety Information

USE

YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1% is a prescription eye drop for adults with blurry close-up vision due to age.

IMPORTANT SAFETY INFORMATION

Do not use YUVEZZI if you are allergic to any of its ingredients or if you currently have inflammation of the iris (iritis).

Before taking YUVEZZI™, tell your doctor if you have depression, low blood pressure, or circulation problems.

YUVEZZI may cause temporary blurry, dim, or dark vision. If you experience this, avoid driving, using machinery, and participating in hazardous activities. Use caution when night driving and in other activities in low light.

Call your doctor right away if you suddenly have flashes of light, floaters, or vision loss.

Do not let the tip of the vial touch your eye, eyelid, or any other surface.

The most common side effects of YUVEZZI are headache, impaired vision, and eye pain and/or eye irritation upon use. These are not all of the possible side effects of YUVEZZI.

Most side effects were generally mild, didn't last long, and went away on their own.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](#), or call 1-800-FDA-1088.

Please see the [Brief Summary](#) for more information.

A

📎

🔄

😊

🗑️

Send

1. American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at: [https://www.aoa.org/DOCS/Advocacy/101/Presbyopia%20for%20Pract%20Final.pdf](#)

2. National Eye Institute. Presbyopia. National Eye Institute. December 4, 2024. [https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/presbyopia](#). Accessed March 30, 2025.

3. Chouinard A, Campbell MCV. Biometric, optical and physical changes in the isolated human crystalline lens with age in relation to presbyopia. Vision Research. 1992;32:1191-1203. doi:10.1016/0042-6969(92)90283-1. [https://www.sciencedirect.com/science/article/pii/S0042696992902831?via=ihl](#)

4. YUVEZZI US Prescribing Information.

MAT-US-YZ-0238

WEBSITE LANGUAGE

This language can be incorporated into your website to share the news of YUVEZZI™ availability at your practice. There is an opportunity to insert your practice name and phone number in the fields noted in pink.

You may select one of the below logos or product images to pair with the website copy. Do not alter the images in any way or use them for any purpose other than for posting with the website language.



LOGOS



PRODUCT IMAGES



FACT SHEET

This material can be used to provide background on YUVEZZI™. It can be shared with media or patients via email or printed in its entirety.

YUVEZZI™
Carbachol and Brimonidine Ophthalmic Solution 1.25%/0.1%

Introducing an innovative treatment option for blurry close-up vision

NOW AVAILABLE

SEE YA LATER SQUINT

SAY HELLO TO THE FUSS-LESS EYE DROP FOR BLURRY CLOSE-UP VISION!

What is YUVEZZI™?
YUVEZZI is a once daily eye drop for blurry close-up vision due to age, also called presbyopia.¹
It is the first and only eye drop that combines two active ingredients that work together to improve near vision.²
- Carbachol helps your pupils get smaller (or "constrict"), making it easier to focus up close
- Brimonidine helps keep your pupils from getting too large (or "dilatating")

What is presbyopia?
As our eyes age, close-up vision may become blurry.¹
The lens in your eye stiffens slowly over time, making it harder to focus on close-up objects.³ Simple things like reading, texting, or checking a label may become harder without holding objects farther away or relying on reading glasses.

IT'S NOT JUST YOU:
About **9 in 10** adults over age 45 in the U.S. have presbyopia⁴

1 DROP

vision with YUVEZZI eye drops.^{2,3}
on its own instead of reading glasses OR
far away.^{2,3} Wait at least 10 minutes after using YUVEZZI before you put them back in your eyes.

**er taking YUVEZZI, some people could clearly
w light without losing distance vision.²**

**ment in reading speed compared to those
paired presbyopia safety study:
paired vision (6%) and eye pain (7%) or irritation (14%).^{2,4}**
and went away on their own.²



YEZZI visit: YUVEZZI.com

% is a prescription eye drop for adults with blurry close-up vision
have inflammation of the iris (iris),
or circulation problems.
ed driving, using machinery, and participating in hazardous
and/or eye irritation upon use. There are not all of the
www.fda.gov/medwatch, or call 1-800-FDA-1088.
November 5, 2025. Available at <https://www.aaa.org/>
age in relation to presbyopia. Vision Research.

MAT-US-YZ-0244

SOCIAL MEDIA POSTS

We've provided social posts to use on your channel(s) to promote the availability of YUVEZZI™. Please ensure the comments are turned OFF on the posts sharing information about YUVEZZI.



Struggling with blurry close-up vision? You're not alone.

YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily prescription eye drop for adults with blurry close-up vision due to age, a condition called presbyopia.

In medical studies, YUVEZZI provided up to 8 continuous hours of improved, close-up vision*.

Contact us to schedule an appointment and discuss whether YUVEZZI may be right for you.

READY FOR YUVEZZI ANIMATED VIDEO

This video can be used with patients to introduce them to YUVEZZI™ and provide information on how to use it, how it works, and common side effects.



FAQ

This material is for your use only and should be referenced for approved messages that you can deliver in conversations with media on the approval and availability of YUVEZZI™. Please note that these messages are not to be distributed and must be used exactly as instructed.



IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients.

WARNINGS AND PRECAUTIONS

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics. Advise patients to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal tear and detachment have been reported with miotics. Individuals with pre-existing retinal disease are at increased risk. Examination of the retina is advised in all patients prior to the initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

YUVEZZI is not recommended to be used when iritis is present.

Avoid touching the vial to the eye, eyelids, or to any other surface.

YUVEZZI may potentiate syndromes associated with vascular insufficiency.

DRUG INTERACTIONS

- Antihypertensives/cardiac glycosides, tricyclic antidepressants, and monoamine oxidase inhibitors: caution advised.
- CNS depressants: consider the possibility of additive or potentiating effects.

ADVERSE REACTIONS

The most common adverse reactions were eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache. The majority of adverse events were mild, transient, and self-resolving.

To report SUSPECTED ADVERSE REACTIONS, contact Visus Therapeutics, Inc., at 1-888-735-0821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional safety information, see the Full Prescribing Information.

INDICATION

YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1% is indicated for the treatment of presbyopia in adults.